Compare FHTX & DMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHTX | DMO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.1M | 108.8M |
| IPO Year | 2020 | 2009 |
| Metric | FHTX | DMO |
|---|---|---|
| Price | $1.77 | $9.33 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $4.17 | N/A |
| AVG Volume (30 Days) | ★ 647.0K | 57.0K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $30,909,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.17 | ★ N/A |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $1.77 | $9.29 |
| 52 Week High | $7.61 | $12.05 |
| Indicator | FHTX | DMO |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 36.55 |
| Support Level | N/A | $9.29 |
| Resistance Level | $2.28 | $9.74 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 8.18 | 6.48 |
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.